PDL BioPharma (PDLI) Guides Q4, FY11 Revs Below Views
PDLI Hot Sheet
Revenue Growth %: -7.0%Financial Fact:
Royalties: 77.34M
Today's EPS Names:
TARO, BRLI, TLB, More
PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced revenue guidance for the fourth quarter ending December 31, 2011 of approximately $72 million, as compared with actual results of $76 million for the fourth quarter of 2010, a five percent decrease. Total anticipated revenue for the year ended December 31, 2011 is $361 million as compared with actual results of $345 million for the year ended December 31, 2010, a five percent increase.
The Street sees Q4 revs of $82.46 million and FY11 revs of $371.79 million.
he forecasted fourth quarter 2011 revenue decline is primarily driven by reduced royalties from third quarter 2011 sales of Avastin® and Herceptin® partially offset by increased royalties from third quarter 2011 sales of Lucentis® and Tysabri®. Sales of Avastin, Herceptin, Lucentis, and Xolair® (the Genentech Products) are subject to a tiered royalty rate for product that is made or sold in the United States and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
The Street sees Q4 revs of $82.46 million and FY11 revs of $371.79 million.
he forecasted fourth quarter 2011 revenue decline is primarily driven by reduced royalties from third quarter 2011 sales of Avastin® and Herceptin® partially offset by increased royalties from third quarter 2011 sales of Lucentis® and Tysabri®. Sales of Avastin, Herceptin, Lucentis, and Xolair® (the Genentech Products) are subject to a tiered royalty rate for product that is made or sold in the United States and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Monro Muffler (MNRO) Tops Q4 EPS by 1c; Comps About Flat; Guides FY13 EPS Below Views
- Synopsys, Inc. (SNPS) Misses Q2 EPS by 2c; Issues Confident Q3 Outlook; Guides FY12
- NetApp (NTAP) Slammed On Weak Outlook
Create E-mail Alert Related Categories
Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
